Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00977574
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:00.262658+00:00
Published At
2018-02-27T00:00:00+00:00
Record Updated At
2025-10-31
Results Posted At
2018-02-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage", "Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-31"
protocolSection.identificationModule.nctId
"NCT00977574"
protocolSection.identificationModule.officialTitle
"A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-02-27"

Study condition terms

  • Endometrial Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Adenosquamous Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Clear Cell Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Serous Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Malignant Uterine Corpus Neoplasm (protocolSection.conditionsModule.conditions)
  • Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage (protocolSection.conditionsModule.conditions)
  • Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage (protocolSection.conditionsModule.conditions)
  • Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage (protocolSection.conditionsModule.conditions)
  • Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage (protocolSection.conditionsModule.conditions)
  • Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.